Recall medication for high blood pressure due to the presence of a small amount of carcinogen

Macleods Pharmaceuticals Limited recalls a lot of Losartan potassium and hydrochlorothiazide combination tablets, as they could contain a carcinogenic substance.

According to

US Food and Drug Administration website,

the tablets, which treat hypertension and hypertensive patients with left ventricular hypertrophy, contained small amounts of N-nitrosodiethylamine (NDEA).

The recalled 100 mg / 25 mg tablets include:

NDC		Maker		Product Description		Lot / Lot		Expiration date
33342-0052-10		Macleods Pharmaceuticals Limited		Losartan Potassium / Hydrochlorothiazide combination tablets 100 mg / 25 mg, bottles of 90		BLM715A		July -1919

PREVIOUS REMINDER:

Losartan: Recall of drugs used to treat hypertension due to trace amounts of potentially carcinogenic chemicals

"Patients taking Losartan Potassium / Hydrochlorothiazide tablets in combination, USP should continue to take their medications because the risk of harm to the patient's health may be greater if the treatment is stopped immediately without further treatment."

Anyone with any general questions about the return of this product should contact Qualanex by email at the address

[email protected]

or call 888-280-2042 (Monday to Friday, 7 am to 4 pm Paris time).

To read the full press release,

click here.